All In Biotech

Drug Trial Radar · NCT07437105

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-272 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Feb 25, 2026

Primary completion

Jun 26, 2027

Study completion Jun 26, 2027

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272 in combination with deutivacaftor (D-IVA) with or without tezacaftor (TEZ) in healthy subjects.

Conditions

  • Cystic Fibrosis

Interventions

  • VX-272Drug

    Suspension for Oral Administration.

  • PlaceboDrug

    Suspension for Oral Administration.

  • TezacaftorDrug

    Tablet for oral administration.

  • DeutivacaftorDrug

    Tablet for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 34)
  2. Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 66)
  3. Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 66)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion - Tempe

    Tempe, Arizona · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.